Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mild cognitive impairment: emerging therapeutics.

J J Sramek1, A E Veroff, N R Cutler

  • 1California Clinical Trials, Beverly Hills, USA. sramek@cctrials.com

The Annals of Pharmacotherapy
|October 31, 2000
PubMed
Summary

Mild cognitive impairment (MCI) is a condition characterized by memory loss, often preceding Alzheimer's disease (AD). Early screening for MCI may aid in the early intervention and prevention of AD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.

The journal of prevention of Alzheimer's disease·2022
Same author

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?

Journal of thrombosis and haemostasis : JTH·2012
Same author

Pharmacokinetics of rizatriptan tablets during and between migraine attacks.

Headache·2004
Same author

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.

Journal of neural transmission (Vienna, Austria : 1996)·2002
Same author

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.

Journal of human hypertension·2002

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Occasional forgetfulness is common in aging.
  • Mild cognitive impairment (MCI) is a condition preceding dementia.
  • MCI is characterized by abnormal memory impairment for age and education.

Purpose of the Study:

  • Provide an overview of MCI etiology, definition, and prevalence.
  • Outline potential treatment strategies for MCI.
  • Discuss MCI as a potential marker for early Alzheimer's disease (AD) onset.

Main Methods:

  • Conducted a MEDLINE search (1990-2000) for MCI, mild-to-moderate AD, and therapeutics.
  • Included data from relevant books and authors' experience in MCI trials.
  • Assessed all references and included relevant information in the review.

Main Results:

  • MCI is a condition in forgetful individuals who are likely to develop AD.
  • MCI is marked by memory impairment abnormal for age and education.
  • MCI can serve as a potential marker for early AD onset.

Conclusions:

  • A significant portion of forgetful individuals, especially those with MCI, may be diagnosed with dementia.
  • MCI is considered by many researchers to be incipient AD.
  • MCI screening may benefit early AD intervention and prevention.

Related Experiment Videos